Senseonics (SENS) Q4 2025 earnings review
Hyper-Growth Top Line, Deepening Bottom Line Losses
Senseonics delivered a massive Q4 top-line beat, with revenue surging 72% year-over-year to $14.3 million. The launch of the Eversense 365 and aggressive direct-to-consumer (DTC) marketing drove a 103% increase in U.S. new patient growth for the year. However, this growth came at a steep price: SG&A expenses exploded by $10.9M year-over-year to $19.8M, pushing Net Loss to $20.8 million despite gross margins hitting 53.8%. The critical narrative shift is the termination of the Ascensia distribution agreement; Senseonics is taking commercialization in-house for 2026. This bold move is projected to drive 2026 revenue to $58-$62M (up ~70%), but it introduces immense execution risk and an immediate Q1 inventory headwind.
🐂 Bull Case
By ending the Ascensia revenue-share agreement, Senseonics will recognize ~20% more revenue per unit. This structural change cements the path to maintaining ~50% gross margins going forward.
103% U.S. new patient growth proves the value proposition of a once-a-year sensor. The upcoming European launch and integration with the twiist Automated Insulin Delivery (AID) system expand the total addressable market.
🐻 Bear Case
The company burned significant cash as SG&A spiked to $19.8M in Q4 alone. With $94.3M in cash remaining, the cost of funding an in-house commercial and DTC machine could force further dilution if the 2026 revenue ramp falters.
Management previously warned that shifting from Ascensia's 60-90 days of channel inventory down to 30 days will create a 1-2 month gap in revenue recognition early in 2026, creating a steep sequential deceleration.
⚖️ Verdict: ⚪
Neutral. The top-line momentum and 50% gross margin target are highly encouraging. However, the sheer cost of acquiring patients and the immense execution risk of building an in-house commercial team overnight keep us sidelined until the Q1 transition noise clears.
Key Themes
Commercial Reintegration Unlocks Gross Margin
Senseonics executed agreements to take back commercialization from Ascensia effective January 1, 2026. This is the biggest fundamental shift in the company's model. By eliminating the revenue-share layer, Senseonics captures the full Average Selling Price (ASP). This dynamic already began lifting Q4 gross profit to $7.7M (53.8% margin), and supports the aggressive 2026 revenue guidance of $58-$62M.
The Cost of Growth: SG&A Explosion
A major data point contradicts the positive revenue narrative: the cost to acquire this revenue is skyrocketing. Q4 SG&A increased by $10.9M YoY to hit $19.8M, far outpacing the $7.7M in gross profit. Management attributes this to heavy DTC marketing investments and the personnel costs of building the in-house commercial team. This negative operating leverage must be monitored closely.
DTC Marketing Fueling Triple-Digit Patient Growth
Direct-to-consumer advertising remains the primary engine for top-line volume. The strategy is clearly working, driving a 103% YoY increase in U.S. new patient starts for 2025. Furthermore, active prescribers grew over 80%. The Eon Care inserter network also scaled to cover 24% of all U.S. insertions, effectively removing the surgical friction that historically blocked CGM adoption.
Expanding Ecosystem: AID Integration & EU Launch
Senseonics achieved two massive pipeline milestones in Q4. First, they launched integration with the twiist Automated Insulin Delivery (AID) System in the U.S., allowing Eversense to compete directly in the lucrative 'closed-loop' pump market. Second, they secured the CE Mark for Eversense 365, setting the stage for a European commercial rollout in 2026.
Q1 2026 Inventory Channel Headwind
As telegraphed in prior quarters, taking commercialization away from Ascensia involves an inventory reset. Ascensia historically held 60-90 days of channel inventory; Senseonics targets 30 days. This destocking will create a sudden, 1-to-2 month revenue recognition void in Q1 2026, heavily back-weighting the $58-$62M annual guidance and threatening Q1 sequential comparisons.
Execution Risk of In-House Transition
Transitioning a highly specialized medical device sales operation in-house is historically fraught with disruption. Senseonics must rapidly scale CRM/ERP systems, manage complex European distribution networks, and retain sales momentum simultaneously. Any friction in this handover will directly impact the ambitious 2026 growth targets.
Macro Uncertainty and Tariff Exposure
Management explicitly cited the effects of tariffs as a risk factor in their 2026 financial outlook. With hardware components sourced internationally and the impending European launch complicating the supply chain, global trade friction could pressure the targeted 50% gross margin.
Other KPIs
Accelerating. Up 57% year-over-year from $22.5 million in 2024. The U.S. market accounted for the vast majority of growth, contributing $27.9 million (up 82% YoY), while Outside the U.S. (OUS) revenue remained mostly flat at $7.4 million.
Stable quarter-over-quarter but representing a tight runway. With a full-year net loss of $69.1M and a Q4 cash burn accelerated by commercial transition costs, this balance sheet provides a limited buffer if 2026 revenue execution stumbles. Outstanding debt sits at $35.3M.
Guidance
Accelerating in absolute dollars. The midpoint of $60M implies a 70% YoY growth rate. This is a massive jump, entirely predicated on realizing the full ASP of the sensors post-Ascensia transition and a successful European launch.
Stable vs 25Q4. Maintaining a 50% margin for the full year would represent a dramatic transformation from FY24's 2% margin, reflecting the permanent elimination of Ascensia's revenue cut and the higher margin profile of the 365-day product.
Key Questions
Q1 Inventory Drawdown Depth
Can you quantify the exact dollar impact expected in Q1 2026 from reducing channel inventory from 60-90 days down to 30 days? How should we model the sequential revenue drop?
SG&A Run Rate
With SG&A spiking to nearly $20M in Q4 as you built the in-house commercial team, should we consider this the new quarterly run-rate, or were there one-time transition costs embedded in that figure?
European Commercial Build-out
Now that CE Mark is secured, what is the exact timeline and capital requirement for establishing the direct sales force in Europe? Are you targeting specific countries first?
twiist Integration Ramp
With the twiist AID integration launched, what are the early adoption metrics? Are you seeing net-new patient starts specifically driven by pump compatibility, or is it mostly existing Eversense users switching pumps?